prostate specific antigen

Summary

Summary: A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

Top Publications

  1. ncbi Screening and prostate-cancer mortality in a randomized European study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    N Engl J Med 360:1320-8. 2009
  2. ncbi Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
    N Engl J Med 350:2239-46. 2004
  3. pmc Mortality results from a randomized prostate-cancer screening trial
    Gerald L Andriole
    Washington University School of Medicine, St Louis, USA
    N Engl J Med 360:1310-9. 2009
  4. ncbi Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer
    Lionel L Banez
    Division of Urologic Surgery and Duke Prostate Center, and Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    J Urol 184:149-56. 2010
  5. ncbi Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:1756-64. 1996
  6. ncbi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
    JAMA 294:66-70. 2005
  7. pmc Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005
    H Gilbert Welch
    VA Outcomes Group 111B, Department of Veterans Affairs Medical Center, White River Junction, VT 05009, USA
    J Natl Cancer Inst 101:1325-9. 2009
  8. ncbi Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer
    Timothy J Wilt
    University of Minnesota School of Medicine, Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research, Minneapolis, Minnesota 55417, USA
    Ann Intern Med 148:435-48. 2008
  9. ncbi DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer
    Daphne Hessels
    Department of Experimental Urology, Nijmegen Center for Molecular Life Sciences, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Eur Urol 44:8-15; discussion 15-6. 2003
  10. ncbi Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer
    Misop Han
    James Buchanan Brady Urological Institute, Departments of Urology, Oncology and Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 169:517-23. 2003

Detail Information

Publications363 found, 100 shown here

  1. ncbi Screening and prostate-cancer mortality in a randomized European study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    N Engl J Med 360:1320-8. 2009
    ..The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer...
  2. ncbi Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
    N Engl J Med 350:2239-46. 2004
    ..We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less...
  3. pmc Mortality results from a randomized prostate-cancer screening trial
    Gerald L Andriole
    Washington University School of Medicine, St Louis, USA
    N Engl J Med 360:1310-9. 2009
    ..This is the first report from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial on prostate-cancer mortality...
  4. ncbi Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer
    Lionel L Banez
    Division of Urologic Surgery and Duke Prostate Center, and Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    J Urol 184:149-56. 2010
    ..In the current study we validated PITX2 methylation status as a biochemical recurrence predictor after radical prostatectomy using a novel microarray based platform in a multi-institutional setting...
  5. ncbi Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:1756-64. 1996
    ..To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant end points of palliation in a randomized controlled trial...
  6. ncbi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
    JAMA 294:66-70. 2005
    ..Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer...
  7. pmc Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005
    H Gilbert Welch
    VA Outcomes Group 111B, Department of Veterans Affairs Medical Center, White River Junction, VT 05009, USA
    J Natl Cancer Inst 101:1325-9. 2009
    ..Systematic estimates of the number of men affected, however, to our knowledge, do not exist...
  8. ncbi Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer
    Timothy J Wilt
    University of Minnesota School of Medicine, Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research, Minneapolis, Minnesota 55417, USA
    Ann Intern Med 148:435-48. 2008
    ..The comparative effectiveness of localized prostate cancer treatments is largely unknown...
  9. ncbi DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer
    Daphne Hessels
    Department of Experimental Urology, Nijmegen Center for Molecular Life Sciences, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Eur Urol 44:8-15; discussion 15-6. 2003
    ..DD3(PCA3) is the most prostate cancer-specific gene described to date. To assess the clinical utility of DD3(PCA3) a time-resolved fluorescence-based, quantitative RT-PCR analysis for DD3(PCA3) was developed...
  10. ncbi Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer
    Misop Han
    James Buchanan Brady Urological Institute, Departments of Urology, Oncology and Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 169:517-23. 2003
    ..radical retropubic prostatectomy to identify clinical and/or pathological indicators of biochemical (prostate specific antigen [PSA]) recurrence...
  11. ncbi Androgen receptor in prostate cancer
    Cynthia A Heinlein
    George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester, Rochester, NY 14642, USA
    Endocr Rev 25:276-308. 2004
    ..The inhibition of AR activity through mechanisms in addition to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression...
  12. pmc AR, the cell cycle, and prostate cancer
    Steven P Balk
    Cancer Biology Program Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Nucl Recept Signal 6:e001. 2008
    ..As will be discussed, discrete aberrations in this process can alter the proliferative response to androgen, and potentially subvert hormonal control of tumor progression...
  13. ncbi Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    J Natl Cancer Inst 98:529-34. 2006
    ..We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer...
  14. pmc Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context
    Gerrit Draisma
    Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 101:374-83. 2009
    ..Reported overdiagnosis estimates have also been variable, ranging from 25% to greater than 80% of screen-detected cancers...
  15. ncbi Prostate specific antigen best practice statement: 2009 update
    Kirsten L Greene
    American Urological Association Education and Research, Inc, Linthicum, Maryland 21090, USA
    J Urol 182:2232-41. 2009
    ..We provide current information on the use of PSA testing for the evaluation of men at risk for prostate cancer, and the risks and benefits of early detection...
  16. ncbi Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
    B Djavan
    Department of Urology, University of Vienna, Vienna, Austria
    J Urol 166:1679-83. 2001
    ..as well as biopsy related morbidity of prostate cancer detected on biopsies 2, 3 and 4 in men with total serum prostate specific antigen (PSA) between 4 and 10 ng./ml. These features were compared to those detected on prostate biopsy 1.
  17. pmc Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BMJ 341:c4521. 2010
    To determine the relation between concentrations of prostate specific antigen at age 60 and subsequent diagnosis of clinically relevant prostate cancer in an unscreened population to evaluate whether screening for prostate cancer and ..
  18. ncbi Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
    Hans Lilja
    Department of Surgery Urology, Memorial Sloan Kettering Cancer Center New York, New York 10065, USA
    Nat Rev Cancer 8:268-78. 2008
    ..Much current research is directed at establishing the most appropriate uses of PSA testing and at developing methods to improve on the conventional PSA test...
  19. ncbi Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy
    Byung Kwan Park
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Invest Radiol 43:789-93. 2008
    ..To assess the use of diffusion-weighted imaging (DWI) at 3 Tesla (T) for lesion localization in patients with a high risk of prostate cancer before a rebiopsy...
  20. pmc A systematic review of the diagnostic accuracy of prostate specific antigen
    Philip Harvey
    School of Medicine, University of Birmingham, Birmingham, UK
    BMC Urol 9:14. 2009
    ..The focus of this review was restricted to European populations as tPSA levels are known to vary by population group...
  21. ncbi Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells
    X Y Sun
    Metabolism and Cancer Susceptibility Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA
    Carcinogenesis 22:1775-80. 2001
    b>Prostate specific antigen, the clinical marker for prostate cancer, is a neutral serine protease whose function is to lyse seminal proteins...
  22. ncbi Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen
    William J Catalona
    Washington University, St Louis, Missouri, USA
    J Urol 171:2239-44. 2004
    Pro forms of prostate specific antigen (PSA) have been reported to be more cancer specific markers of prostate cancer than total PSA and they also may preferentially detect the more aggressive forms of the disease.
  23. ncbi Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer
    Cheol Kwak
    Department of Urology, Seoul National University College of Medicine and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea
    J Urol 168:995-1000. 2002
    We determine whether the nadir prostate specific antigen (PSA) level after hormone therapy can be used to predict the progression to hormone refractory prostate cancer.
  24. ncbi Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy
    Chikara Ohyama
    Department of Urology, Akita University School of Medicine, Akita, Japan
    Glycobiology 14:671-9. 2004
    ..These results suggest that the differential binding of free serum PSA to M. amurensis agglutinin lectin between prostate cancer and benign prostate hypertrophy could be a potential measure for diagnosis of prostate cancer...
  25. ncbi Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen
    Thomas Hambrock
    University Medical Centre St Radboud, Nijmegen, The Netherlands
    J Urol 183:520-7. 2010
    Undetected cancer in repeat transrectal ultrasound guided prostate biopsies in patients with increased prostate specific antigen greater than 4 ng/ml is a considerable concern...
  26. pmc Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells
    Xin Yuan
    Hematology Oncology Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Am J Pathol 169:682-96. 2006
    ..These results reveal a potentially critical function of AR in androgen-independent PCa that is distinct from its previously described transcriptional or nontranscriptional functions...
  27. ncbi Effect of finasteride on the sensitivity of PSA for detecting prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    J Natl Cancer Inst 98:1128-33. 2006
    ..We examined the impact of finasteride on the sensitivity and area under the receiver operating characteristic curve (AUC) of prostate-specific antigen (PSA) for detecting prostate cancer...
  28. ncbi Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
    Sven Perner
    Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:696-701. 2007
    ..6-9.7, P < .001, respectively). In summary, PSMA is independently associated with PSA recurrence in a high-risk cohort and thus might provide insight into the additional use of adjuvant therapy. Validation on other cohorts is required...
  29. ncbi Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma
    Jonas Hugosson
    Department of Urology, Sahlrenska University Hospital, Gothenburg, Sweden
    Cancer 100:1397-405. 2004
    ..The purpose of the current study was to evaluate the effectiveness of a prostate carcinoma screening program in which serum prostate-specific antigen (PSA) levels were measured...
  30. ncbi Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA
    Glòria Tabarés
    Unitat de Bioquímica i Biologia Molecular, Department de Biologia Universitat de Girona, Campus de Montilivi s n 17071, Girona, Catalonia, Spain
    Glycobiology 16:132-45. 2006
    ..Further analysis of the glycosylation of PSA from PCa and BPH sera will be required in order to determine the utility of these glycan differences to discriminate specifically between benign and malignant prostate states...
  31. ncbi Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    JAMA 291:1325-32. 2004
    ..Salvage radiotherapy may potentially cure patients with disease recurrence after radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at the highest risk of metastatic disease progression...
  32. ncbi Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
    Judd W Moul
    Department of Surgery, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda 20852, USA
    J Urol 171:1141-7. 2004
    Hormonal therapy (HT) is the current mainstay of systemic treatment for prostate specific antigen (PSA) only recurrence (PSAR), however, there is virtually no published literature comparing HT to observation in the clinical setting...
  33. pmc Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells
    Chih Pin Chuu
    The Ben May Department for Cancer Research, The University of Chicago, 929 East 57th Street, CIS W325F, Chicago, IL 60637, USA
    Cancer Lett 275:86-92. 2009
    ..EGCG suppressed cell proliferation, prostate specific antigen (PSA) expression, and AR transcriptional activity in the different LNCaP sublines...
  34. pmc [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study
    Brian V Le
    Department of Urology, Northwestern University, Chicago, Illinois 60611, USA
    J Urol 183:1355-9. 2010
    Due to the limited specificity of prostate specific antigen for prostate cancer screening, there is an ongoing search for adjunctive biomarkers...
  35. ncbi Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer
    Cheng Jiang
    Hormel Institute, University of Minnesota, Austin, Minnesota 55912, USA
    Cancer Res 66:453-63. 2006
    ..The novel antiandrogen and AR activities of decursin and decursin-containing herbal extracts have significant implications for the chemoprevention and treatment of prostate cancer and other androgen-dependent diseases...
  36. ncbi Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram
    E W Steyerberg
    Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Urol 177:107-12; discussion 112. 2007
    Screening with serum prostate specific antigen testing leads to the detection of many prostate cancers early in their natural history. Statistical models have been proposed to predict indolent cancer...
  37. ncbi Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience
    Ahmed Magheli
    Department of Urology, Charité Hospital Berlin, Campus Mitte, University Medicine Berlin, Berlin, Germany
    J Urol 183:126-31. 2010
    We investigated the value of pretreatment prostate specific antigen density to predict Gleason score upgrading in light of significant changes in grading routine in the last 2 decades.
  38. ncbi In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors
    Robert Snoek
    Prostate Center at Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, British Columbia, Canada
    Clin Cancer Res 15:39-47. 2009
    ..We hypothesize that knocking down AR will have a major effect on inhibiting growth of castration-resistant tumors...
  39. pmc Contemporary risk profile of prostate cancer in the United States
    Yu Hsuan Shao
    Department of Population Science, Cancer Institute of New Jersey, New Brunswick, NJ, USA
    J Natl Cancer Inst 101:1280-3. 2009
    ..In conclusion, more men were diagnosed with prostate cancer at a younger age and earlier stage in 2004-2005 than in earlier years. The racial disparity in cancer stage at diagnosis has decreased statistically significantly over time...
  40. ncbi Characterization of C4-2 prostate cancer bone metastases and their response to castration
    Jesco Pfitzenmaier
    Department of Urology, University of Washington, Seattle 98195, Washington, USA
    J Bone Miner Res 18:1882-8. 2003
    ..Here we describe characterization of a model consisting of direct injection of C4-2 cells into tibias...
  41. ncbi Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml
    Masood A Khan
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    J Urol 170:723-6. 2003
    In contemporary screening populations a major drawback of prostate specific antigen (PSA) is its relative lack of specificity, especially in the range of 4 to 10 ng/ml, where prostate cancer is found 25% of the time...
  42. ncbi Screening for prostate cancer in high risk populations
    William J Catalona
    Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA
    J Urol 168:1980-3; discussion 1983-4. 2002
    ..Consequently, screening at a younger age has been recommended for high risk men, however, there are limited data on actual screening results in young, high risk populations...
  43. ncbi Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer
    Alvaro A Martinez
    Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073, USA
    Int J Radiat Oncol Biol Phys 53:316-27. 2002
    ....
  44. ncbi Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study
    J M Chan
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
    Science 279:563-6. 1998
    ..This association was independent of baseline prostate-specific antigen levels. Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk reduction and treatment...
  45. pmc From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
    S Yeh
    George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and the Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Proc Natl Acad Sci U S A 96:5458-63. 1999
    ..Together, these data provide a novel pathway from HER2/Neu to AR transactivation, and they may represent one of the reasons for the PSA re-elevation and hormone resistance during androgen ablation therapy in prostate cancer patients...
  46. ncbi Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years
    Hans Lilja
    Department of Laboratory Medicine, Lund University, University Hospital UMAS, Malmo, Sweden
    J Clin Oncol 25:431-6. 2007
    ..We examined whether prostate-specific antigen (PSA) forms and human kallikrein 2 (hK2) measured at age 44 to 50 years predict long-term risk of incident prostate cancer...
  47. pmc Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors
    Axel Heiser
    Cancer Immunotherapy Program, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 109:409-17. 2002
    ....
  48. ncbi Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    J Clin Oncol 25:669-74. 2007
    ..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel...
  49. ncbi The "male lumpectomy": focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up
    Gary Onik
    Department of Radiology and Urology, Division of Surgical Imaging, Center for Surgical Advancement, Celebration Health Florida Hospital, Celebration, FL 34747, USA
    Urol Oncol 26:500-5. 2008
    ..This raises the question of whether these patients can be identified and treated with a limited "lumpectomy" or focal cancer treatment...
  50. ncbi Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer
    A Pollack
    Departments of Radiation Oncology, Biostatistics, Urology, and Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:3904-11. 2000
    ..To determine the effect of radiotherapy dose on prostate cancer patient outcome and biopsy positivity in a phase III trial...
  51. ncbi Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system
    Steven J Buskirk
    Department of Radiation Oncology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Urol 176:985-90. 2006
    This study was performed to evaluate the results and prognostic factors associated with radiotherapy for a detectable serum prostate specific antigen level after radical prostatectomy.
  52. ncbi Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy
    Cherry T Thomas
    Division of Radiation Oncology, University of Cincinnati, OH, USA
    J Clin Oncol 21:1715-21. 2003
    ..We evaluated the prognostic significance of indium-111 (111In)-capromab pendetide imaging for patients with prostate cancer who underwent salvage radiotherapy (RT) for recurrent disease after prostatectomy...
  53. ncbi Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group
    Fernando E C Calais da Silva
    Department of Urology, Centro Hospitalar de Lisboa Central, Lisbon, Portugal
    Eur Urol 55:1269-77. 2009
    ..Few randomised studies have compared intermittent hormonal therapy (IHT) with continuous therapy for the treatment of advanced prostate cancer (PCa)...
  54. ncbi Rising prostate cancer rates in South Korea
    Sue Kyung Park
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA
    Prostate 66:1285-91. 2006
    ..Prostate cancer incidence and mortality rates in South Korea are relatively low, but rising steadily...
  55. pmc Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen
    Pierre I Karakiewicz
    Department of Urology, University of Montreal, Montreal, Quebec, Canada
    J Urol 173:1930-4. 2005
    ..We developed and validated a nomogram which predicts presence of prostate cancer (PCa) on needle biopsy...
  56. ncbi High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results
    D Jeffrey Demanes
    California Endocurietherapy Cancer Center, Oakland, CA, USA
    Int J Radiat Oncol Biol Phys 61:1306-16. 2005
    ..To present the long-term outcome and morbidity of high-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT) for localized prostate cancer...
  57. ncbi Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study
    Joseph C Presti
    Department of Urology, Stanford University School of Medicine, Stanford, CA, USA
    J Urol 169:125-9. 2003
    We assessed the impact of age and prostate specific antigen (PSA) on extended systematic biopsy schemes for detecting prostate carcinoma and better characterized these tumors as a function of patient age and PSA.
  58. ncbi Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial
    W J Catalona
    Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 279:1542-7. 1998
    ..The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use...
  59. ncbi Serial biopsy results in prostate cancer screening study
    Kimberly A Roehl
    Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA
    J Urol 167:2435-9. 2002
    We evaluated prostate biopsy results in men with elevated prostate specific antigen (PSA) levels and/or suspicious digital rectal examination whose initial biopsies did not reveal cancer.
  60. ncbi Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 65:965-74. 2006
    ..The ASTRO definition defined prostate specific antigen (PSA) failure as occurring after three consecutive PSA rises after a nadir with the date of failure as ..
  61. pmc Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy
    C Shad Thaxton
    Department of Urology, Northwestern University Feinberg School of Medicine, 303 East Chicago, Chicago, IL 60611, USA
    Proc Natl Acad Sci U S A 106:18437-42. 2009
    ..development of a previously undescribed gold nanoparticle bio-barcode assay probe for the detection of prostate specific antigen (PSA) at 330 fg/mL, automation of the assay, and the results of a clinical pilot study designed to ..
  62. ncbi Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
    Neil H Bander
    Department of Urology, Weill Medical College of Cornell University, 525 E 68th St, E 300, New York, NY 10021, USA
    J Clin Oncol 23:4591-601. 2005
    ....
  63. ncbi Insignificant prostate cancer and active surveillance: from definition to clinical implications
    Patrick J Bastian
    Urologische Klinik und Poliklinik, Universitätsklinikun der Universität München Grosshadern, Ludwig Maximilians Universitat, Munich, Germany
    Eur Urol 55:1321-30. 2009
    ..It remains unclear whether all patients diagnosed with prostate cancer warrant radical treatment or may benefit from delayed intervention following active surveillance...
  64. ncbi A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy
    Joseph A Smith
    Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2765, USA
    J Urol 178:2385-9; discussion 2389-90. 2007
    ..We evaluated the incidence and location of positive surgical margins in 200 sequential robotic assisted laparoscopic radical prostatectomy and 200 sequential open radical retropubic prostatectomy cases...
  65. ncbi Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA
    Gianluca Severi
    Cancer Epidemiology Center, The Cancer Council Victoria, Melbourne, Victoria, Australia
    Cancer Epidemiol Biomarkers Prev 15:1142-7. 2006
    ..The genotypes and haplotypes studied might be associated with the PSA gene function or be in linkage disequilibrium with other unmeasured and functional variants in the PSA or other genes...
  66. ncbi Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line
    Ke Hung Tsui
    Department of Urology, Chang Gung Memorial Hospital, Kwei Shan, Tao Yua, Taiwan, ROC
    Anticancer Res 28:1969-76. 2008
    A novel prostate cancer cell line (PC-J) was isolated from an androgen independent non-prostate specific antigen (non-PSA) producing carcinoma cell line...
  67. ncbi Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era
    Stephen A Boorjian
    Department of Urology and Division of Biostatistics, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 178:864-70; discussion 870-1. 2007
    While the incidence of lymph node positive prostate cancer has decreased during the prostate specific antigen era, the optimal treatment of these patients remains in question...
  68. ncbi Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy
    Raj S Pruthi
    Division of Urologic Surgery, Department of Biostatistics, and Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Clin Cancer Res 12:2172-7. 2006
    ..However, human trials are absent. This study evaluated the efficacy of the COX-2 inhibitor celecoxib in prostate-specific antigen (PSA) recurrent prostate cancer after radiation therapy (X-ray therapy or XRT) or radical prostatectomy...
  69. ncbi Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation
    Madan L Nagpal
    Research Service, WJB Dorn Veterans Medical Center, Columbia, SC 29209, USA
    Biochim Biophys Acta 1762:811-8. 2006
    ..These results indicated that CXCL10 inhibited LNCaP cell proliferation and decreased PSA production by up-regulation of CXCR3 receptor. CXCL10 may be potentially useful in the treatment of prostate cancer...
  70. ncbi One-step immunostrip test for the simultaneous detection of free and total prostate specific antigen in serum
    Cesar Fernandez-Sanchez
    School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle upon Tyne, UK
    J Immunol Methods 307:1-12. 2005
    ..on a strip format for the rapid and reliable simultaneous detection of serum levels of free and total prostate specific antigen (f-PSA and t-PSA) and estimation of f-PSA to t-PSA ratio (f/t-PSA) is reported...
  71. ncbi The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance
    Martijn P M Q van Gils
    Department of Urology, Radboud University Nijmegen Medical Centre, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
    Clin Cancer Res 13:939-43. 2007
    ..In a previous single institution study, the PCA3 urine test clearly proved to be of diagnostic value. Therefore, the diagnostic performance of the PCA3 urine test was validated in a multicenter study...
  72. ncbi Persistent intraprostatic androgen concentrations after medical castration in healthy men
    Stephanie T Page
    University of Washington Medical Center, Division of Metabolism, Endocrinology and Nutrition, Box 357138, 1959 NE Pacific, Seattle, WA 98195
    J Clin Endocrinol Metab 91:3850-6. 2006
    ..Studies of men with prostate cancer have suggested that prostatic androgens are preserved in the setting of castration. Tissue androgens might stimulate prostate growth, producing adverse clinical consequences...
  73. ncbi Does PSA velocity predict prostate cancer in pre-screened populations?
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 49:460-5; discussion 465. 2006
    ..An elevated PSA in secondary screens may indicate benign enlargement of the prostate rather than prostate cancer. In such cases the yearly rate of increase of PSA (PSA velocity [PSAV]) may improve the test characteristics of PSA...
  74. ncbi Asymptomatic inflammation and/or infection in benign prostatic hyperplasia
    J C Nickel
    Department of Urology, Queen s University, Kingston, Ontario, Canada
    BJU Int 84:976-81. 1999
    ..To determine the extent, pattern and clinical significance of asymptomatic histological inflammation and latent infection (National Institute of Health Category IV prostatitis) in benign prostatic hyperplasia (BPH)...
  75. ncbi Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid
    T Okada
    Department of Glycobiology, Tokyo Metropolitain Institute of Gerontology, Japan
    Biochim Biophys Acta 1525:149-60. 2001
    ..However, the ratios of each N-glycan were different. These results indicate that PSA-A and PSA-B differ not only in their sialic acid contents, but also in their outer chain features...
  76. ncbi Cardiac glycosides decrease prostate specific antigen expression by down-regulation of prostate derived Ets factor
    Horng Heng Juang
    Department of Anatomy, Chang Gung University, Kwei Shan, Taiwan, Republic of China
    J Urol 184:2158-64. 2010
    ..We evaluated the mechanisms of cardiac glycosides, including digoxin, digitoxin and ouabain (Sigma®), on prostate specific antigen gene expression in vitro.
  77. ncbi Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends
    Ruth Etzioni
    Program in Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 94:981-90. 2002
    ..Overdiagnosis was defined as the detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime...
  78. ncbi American Cancer Society guidelines for the early detection of cancer
    Robert A Smith
    Cancer Control Department, American Cancer Society, Atlanta, GA, USA
    CA Cancer J Clin 52:8-22. 2002
    ....
  79. ncbi Prostate specific antigen density correlates with features of prostate cancer aggressiveness
    Shilajit D Kundu
    Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Urol 177:505-9. 2007
    An increased prostate specific antigen density (serum prostate specific antigen divided by prostate volume) is an established parameter to help determine the need to perform prostate biopsies...
  80. ncbi Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins
    Jwa Min Nam
    Department of Chemistry and Institute for Nanotechnology, Northwestern University, 2145 Sheridan Road, Evanston, IL 60201, USA
    Science 301:1884-6. 2003
    ..Comparable clinically accepted conventional assays for detecting the same target have sensitivity limits of approximately 3 picomdar, six orders of magnitude less sensitive than what is observed with this method...
  81. ncbi Rye whole grain and bran intake compared with refined wheat decreases urinary C-peptide, plasma insulin, and prostate specific antigen in men with prostate cancer
    Rikard Landberg
    Department of Food Science, Swedish University of Agriculture Science, Uppsala, Sweden
    J Nutr 140:2180-6. 2010
    ..progression in animal models, including lower tumor take rates, smaller tumor volumes, and reduced prostate specific antigen (PSA) concentrations. A human pilot study showed increased apoptosis after consumption of rye bran bread...
  82. ncbi PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 64:512-7. 2006
    ..To analyze prostate-specific antigen (PSA) kinetics in patients treated with prostate brachytherapy (PI) with a minimum of 5 years of PSA follow-up...
  83. ncbi Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth
    Abraham Morgentaler
    Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Eur Urol 55:310-20. 2009
    ..The traditional belief that prostate cancer (PCa) growth is dependent on serum testosterone (T) level has been challenged by recent negative studies in noncastrated men...
  84. ncbi A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen
    Elizabeth M Grainger
    The Ohio State University, Columbus, Ohio 43210, USA
    Nutr Cancer 60:145-54. 2008
    ..Further studies combining tomato and soy foods to determine efficacy for prostate cancer prevention or management are encouraged...
  85. ncbi Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates
    Joseph F Pazona
    Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    J Urol 174:1282-6. 2005
    We evaluated men treated with salvage radiation therapy for increasing serum prostate specific antigen (PSA) following radical retropubic prostatectomy (RRP).
  86. ncbi Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration
    Siobhan Sutcliffe
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    J Urol 175:1937-42. 2006
    ..We indirectly investigated this question by measuring serum PSA, a possible marker of prostatic inflammation and cell damage, in men with documented STIs...
  87. pmc The influence of extent of surgical margin positivity on prostate specific antigen recurrence
    R E Emerson
    Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, IN 46202, USA
    J Clin Pathol 58:1028-32. 2005
    ..Positive surgical margins are an adverse prognostic factor in patients undergoing prostatectomy for prostate cancer. The extent of margin positivity varies and its influence on clinical outcome is uncertain...
  88. ncbi Do tumor volume, tumor volume ratio, type of nerve sparing and surgical experience affect prostate specific antigen recurrence after laparoscopic radical prostatectomy? A matched pair analysis
    M Ates
    Department of Urology, SLK Klinikum Heilbronn, University of Heidelberg, Heidelberg, Germany
    J Urol 177:1771-5; discussion 1775-6. 2007
    ..We assessed the impact of tumor volume, tumor volume ratio (tumor volume-to-prostate volume), surgical experience and type of nerve sparing procedure on biochemical recurrence after laparoscopic radical prostatectomy...
  89. ncbi Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection
    Stephen J Freedland
    Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    J Urol 175:500-4; discussion 504. 2006
    ..We examined the association between BMI, and PSA and prostate weight in a cohort of men undergoing RP...
  90. ncbi New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era
    Bridget Bickers
    School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, Hampshire PO12DT, UK
    Anticancer Res 29:3289-98. 2009
    ..g. blood, urine) that could more accurately predict disease progression. This review article gives a brief overview of biomarkers that are currently showing prognostic potential in prostate cancer research...
  91. ncbi Exposure to persistent organochlorine pollutants and seminal levels of markers of epididymal and accessory sex gland functions in Swedish men
    A Rignell-Hydbom
    Department of Occupational and Environmental Medicine, Lund University Hospital, SE 221 85 Lund
    Hum Reprod 20:1910-4. 2005
    ..The present study aimed to investigate whether exposure to 2,2',4,4',5,5'-hexachlorobiphenyl (CB-153) and 1,1-dichloro-2,2-bis (p-chlorophenyl)-ethylene (p,p'-DDE) affects epididymal and accessory sex gland function...
  92. ncbi Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features
    Jason S Krumholtz
    Division of Urologic Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Urology 60:469-73; discussion 473-4. 2002
    ..6 to 4.0-ng/mL PSA range and compare them with Stage T1c cancers concurrently detected in the 4.1 to 10.0-ng/mL PSA range. All cancers were detected in a prostate cancer screening study...
  93. ncbi Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer
    J B Welsh
    Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, USA
    Cancer Res 61:5974-8. 2001
    ..Other genes, such as fatty acid synthase, encode enzymes known as drug targets in other contexts, which suggests new therapeutic approaches...
  94. ncbi Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea
    Jae Wook Kim
    Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 146 92 Dogok dong, Kangnam Gu, Seoul 135 720, Korea
    Yonsei Med J 45:671-5. 2004
    ..We randomized 240 men with an elevated serum total prostate specific antigen (PSA) level, abnormal digital rectal examination (DRE) and/or TRUS suspicious for prostate cancer into a ..
  95. ncbi Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology
    Thomas J Polascik
    Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Urology 70:117-21. 2007
    ..We report our initial experience using a transrectal ultrasound-guided, third-generation, argon/helium cryosurgical system...
  96. ncbi Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan
    Shigeru Kosuda
    Department of Radiology, National Defense Medical College, Namiki, Tokorozawa, Japan
    Cancer 94:964-72. 2002
    The objective of the current study was to assess rigorously whether serum prostate specific antigen (PSA) determination can eliminate the need for bone scans in Japanese patients with newly diagnosed prostate carcinoma with serum PSA ..
  97. ncbi Detection of protein analytes via nanoparticle-based bio bar code technology
    Y Paul Bao
    Nanosphere, Inc, 4088 Commercial Avenue, Northbrook, Illinois 60062, USA
    Anal Chem 78:2055-9. 2006
    ....
  98. ncbi Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study
    P Stattin
    Department of Urology and Andrology, Umea University Hospital, Sweden
    J Natl Cancer Inst 92:1910-7. 2000
    ..In this study, we sought to determine the role of IGF-I as well as IGFBPs-1, -2, and -3 and insulin as possible etiologic factors for prostate cancer...
  99. ncbi Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age
    Frank A Critz
    Radiotherapy Clinics of Georgia, 2349 Lawrenceville Highway, Decatur, GA 30033, USA
    J Urol 170:1864-7. 2003
    We report on the relationship of patient age to prostate specific antigen (PSA) bounce after brachytherapy for prostate cancer.
  100. ncbi Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases a Montsouris Institute
    B Guillonneau
    Department of Urology, Institut Mutualiste Montsouris, Paris, France
    J Urol 169:1261-6. 2003
    ..We performed a prospective oncological evaluation of laparoscopic radical prostatectomy in regard to local tumor control and biochemical recurrence...
  101. ncbi Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era
    Jean O Ung
    Department of Urology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Urology 60:458-63. 2002
    ..To demonstrate the evolution of the clinical presentation and pathologic and biochemical outcomes for patients with clinically localized prostate cancer treated with radical prostatectomy during the prostate-specific antigen (PSA) era...

Research Grants71

  1. Gene Networks for Prostate Cancer Progression
    Leif Peterson; Fiscal Year: 2005
    ..tissue during radical retropubic prostatectomy (RPP) and short doubling time (<10 months) for serum prostate specific antigen (PSA)...
  2. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Mona Fouad; Fiscal Year: 2013
    ..Participants will be contacted annually to determine current health status. Follow up includes ascertainment of adverse medical outcomes, cancer incidence, cause of death, and mortality impact. ..
  3. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    BARBARA O'BRIEN; Fiscal Year: 2013
    ..Participants will be contacted annually to determine current health status. Follow up includes ascertainment of adverse medical outcomes, cancer incidence, cause of death, and mortality impact. ..
  4. Robot-Assisted MRI-Guided Prostate Biopsy
    Dan Stoianovici; Fiscal Year: 2010
    ..6 billion. Biopsies are typically triggered by elevated prostate specific antigen (PSA) tests, which are highly sensitive but insufficiently specific for PC...
  5. Tea Polyphenols in Chemoprevention of Prostate Cancer
    SUSANNE MARGARETE HENNING; Fiscal Year: 2011
    ..Serum prostate specific antigen and IGF-1/IGFBP-3 will be determined using chemiluminescent analysis...
  6. Detection of Prostate Cancer Genomic Signatures in Blood
    Amin I Kassis; Fiscal Year: 2010
    ..In this Challenge grant application, we describe methods for the identification of tumor-specific signatures within the WBCs of men known to have prostate cancer. ..
  7. A Molecular targeting agent for systemic radiotherapy of metastatic Prostate Canc
    Kevin P Maresca; Fiscal Year: 2010
    ..Blood PSA (Prostate Specific Antigen) screening and digital rectal exams can detect early warning signs of prostate cancer but an effective ..
  8. CYP19A1 gene and Pharmacogenetics of Response
    REINA C VILLAREAL; Fiscal Year: 2013
    ..abstract_text> ..
  9. PSMA-based Cancer Imaging Agents
    Martin G Pomper; Fiscal Year: 2013
    ..abstract_text> ..
  10. Interactions between CNS-specific human kallikreins and the PA system in inflamma
    Michael Blaber; Fiscal Year: 2009
    ..The goals of the proposal are to understand how such proteases are controlled and how this control can be manipulated to potentially treat diseases of the central nervous system. ..
  11. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Claudine Isaacs; Fiscal Year: 2010
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: - Understand the causes and mechanisms of cancer - Improve early detection and diagnosis ..
  12. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    BARBARA O apos BRIEN; Fiscal Year: 2009
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: - Understand the causes and mechanisms of cancer - Improve early detection and diagnosis..
  13. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Claudine Isaacs; Fiscal Year: 2009
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: - Understand the causes and mechanisms of cancer - Improve early detection and diagnosis..
  14. Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial - Lab
    Cheryl Robinson; Fiscal Year: 2009
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: - Understand the causes and mechanisms of cancer - Improve early detection and diagnosis..
  15. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Mona Fouad; Fiscal Year: 2010
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: Understand the causes and mechanisms of cancer Improve early detection and diagnosis ..
  16. Development of Nonhuman Primate Models for PSA Biology Studies
    JAMES NKAMBWE MUBIRU; Fiscal Year: 2013
    ..These diseases are a cause of significant mortality and morbidity. Prostate specific antigen (PSA) is released at increased levels into the blood early in the development of these diseases and ..
  17. Rel B mediated-redox regulation of radiation therapy
    William H St Clair; Fiscal Year: 2013
    ..from this study will provide insights into the novel mechanisms by which interleukin 8 (IL8) and prostate specific antigen (PSA) are differentially regulated and will test a proof-of-concept for using their relationship to ..
  18. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    BARBARA O'BRIEN; Fiscal Year: 2011
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: - Understand the causes and mechanisms of cancer - Improve early detection and diagnosis ..
  19. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Mona Fouad; Fiscal Year: 2011
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: Understand the causes and mechanisms of cancer Improve early detection and diagnosis ..
  20. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    KAREN STEINMETZ; Fiscal Year: 2011
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: - Understand the causes and mechanisms of cancer - Improve early detection and diagnosis..
  21. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Mona Fouad; Fiscal Year: 2009
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: [unreadable] Understand the causes and mechanisms of cancer [unreadable] Improve early detection and diagnosis..
  22. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    Saundra Buys; Fiscal Year: 2009
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: - Understand the causes and mechanisms of cancer - Improve early detection and diagnosis..
  23. PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Paul Kvale; Fiscal Year: 2010
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: - Understand the causes and mechanisms of cancer - Improve early detection and diagnosis ..
  24. Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial
    BARBARA O apos BRIEN; Fiscal Year: 2010
    ..The PLCO EEMS directly addresses the following strategic priorities of the National Cancer Institute: - Understand the causes and mechanisms of cancer - Improve early detection and diagnosis ..
  25. Proximal Prostate Fluids for Protein and miRNA Biomarkers
    Richard R Drake; Fiscal Year: 2010
    Detection of prostate specific antigen (PSA) levels in serum as a biomarker of prostate cancer continues to evolve to reflect new knowledge about disease-specific isoforms and free versus bound complexes with serum proteins...
  26. SPORE IN PROSTATE CANCER
    WILLIAM GEORGE NELSON; Fiscal Year: 2013
    ..The Research Projects are supported by an Administrative Core (A), which also manages inter-SPORE collaborations, a Tissue Archive Core (B), and a Biostatistics and Epidemiology Core (C). ..
  27. CBP Bromodomain Antagonists Block Androgen Receptor in Prostate Cancer
    SYED S MUJTABA; Fiscal Year: 2010
    ..inhibitor (SMI) of CBP BRD inhibits AR expression and transcriptional activity by downregulating prostate specific antigen (PSA) in LNCaP and PC3 cells...
  28. [F18]FMAU in Prostate Cancer
    Hossein Jadvar; Fiscal Year: 2010
    ....
  29. Radiation Force Imaging of Prostate Cancer and Guidance of Biopsy Procedures
    Kathryn Radabaugh Nightingale; Fiscal Year: 2013
    ....
  30. Prostate Cancer Detection by Molecular Urinalysis
    Christian P Pavlovich; Fiscal Year: 2010
    ..Hopefully, useful biomarker information for prostate cancer will also result from my period of study. ..
  31. Small Integrin-binding Glycophosphoproteins as Biomarkers for Prostate Cancer
    Neal S Fedarko; Fiscal Year: 2013
    ....
  32. VPAC1 Recpetor-Targeted PET Imaging of Prostate Cancer
    MATHEW LAXMAN THAKUR; Fiscal Year: 2013
    ..Serum prostate specific antigen (PSA) measurements, transrectal ultrasonography (TRUS) and magnetic resonance imaging (MRI) remain ..
  33. A Novel Synthetic Androgen Receptor Antagonist
    Zhongyun Dong; Fiscal Year: 2012
    ..The proposed research will establish that DL3 is a novel AR antagonist, will elucidate mechanisms by which DL3 interrupts AR signaling, and will determine therapeutic effects of DL3 against human prostate cancer cells in mice. ..
  34. Alpha Methyl AcylCoa Racemase (AMACR)
    Martin G Pomper; Fiscal Year: 2010
    ..In this project we will develop a high-throughput screen to identify compounds that bind strongly to AMACR, which we can subsequently derivatize for high-sensitivity prostate cancer imaging. ..
  35. A bioelectronic assay for PSA activity
    Dimitra Georganopoulou; Fiscal Year: 2010
    ....
  36. USE AND OUTCOMES OF INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER
    Huei Ting Tsai; Fiscal Year: 2013
    ..S. general practice. Findings from the proposed study will generate new hypotheses regarding the comparative effectiveness of intermittent and continuous ADT and will inform subsequent research to help guide ADT use in prostate cancer. ..
  37. Mitochondrial DNA and Prostate Cancer in African American
    Keshav K Singh; Fiscal Year: 2013
    ..However, when adjusted for age, Gleason grade and PSA (prostate specific antigen) the prostate tumors of AAM contained >6 times less mtDNA than CAM tumors...
  38. Prostate Cancer: Targeting Androgen Receptor Signaling by Tetrandrine
    Hari K Koul; Fiscal Year: 2013
    ..Tet inhibited Prostate Specific Antigen (PSA) synthesis and secretion, blocked cell cycle progression and growth of human PCa cells in culture, ..
  39. Glycoproteins and Glycan-Binding IgGs: Biomarkers for Cancer and Inflammatory Di
    Hyesook Kim; Fiscal Year: 2013
    ..Identification of prostate cancer- specific glycans recognized by autoantibodies will lead to development of glycan-based therapeutics. ..
  40. Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients
    Clement Gwede; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The use of the prostate specific antigen (PSA) test in the general population and identifiable high-risk subgroups remains controversial, and the PSA test remains the only available test to date to ..
  41. Metabolomic Markers for Early Detection of Prostate Cancer
    Arun Sreekumar; Fiscal Year: 2010
    ..Clinically, early detection of prostate cancer is guided by levels of prostate specific antigen (PSA)...
  42. Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial
    Sebastiano Gattoni-Celli; Fiscal Year: 2013
    ..At the same time, Vitamin D3 supplementation would help us identify those patients (non-responders) who are affected by potentially aggressive disease and should consider definitive treatment. ..
  43. Identification of Colon Cancer Protein Biomarkers in the Blood
    WILFRIDO DIOKNO MOJICA; Fiscal Year: 2010
    ..approaches suggest the potential to identify candidate CRC-selective biomarker proteins, akin to Prostate Specific Antigen (PSA) for prostate cancer or CA125 for ovarian cancer...
  44. Blood-based biomarker amplification using high intensity focused ultrasound (HIFU
    Tatiana Khokhlova; Fiscal Year: 2013
    ..g., Prostate Specific Antigen (PSA) tests, often fail to differentiate between the two...
  45. Glycan Biomarkers of Prostate Cancer in Prostatic Fluids
    Richard R Drake; Fiscal Year: 2012
    ..Identification of these molecular markers will improve prostate cancer detection and risk stratification prior to biopsy and prostatectomy procedures. ..
  46. Alcohol Use and High Risk Behavior Among HIV-Positive Men
    SARAH WOOLF-KING; Fiscal Year: 2013
    ..We will accomplish this aim by: (a) using a qualitative test for Prostate Specific Antigen (PSA), an indicator of recent (i.e...
  47. Social network and sexual risk for HIV/STIs among older female sex workers
    Hongjie Liu; Fiscal Year: 2013
    ....
  48. Methylated Galectin-3 DNA as a Marker for Early Diagnosis of Prostate Cancer
    Hafiz Ahmed; Fiscal Year: 2010
    ..Combined with the digital rectal examination, the prostate specific antigen (PSA) test has been widely used to detect prostate cancer in its early stages...
  49. The Role of MicroRNAs in Prostate Cancer Progression
    AURORA ESQUELA KERSCHER; Fiscal Year: 2010
    ..Investigating the function of miRNAs in prostate cancer progression promises to reveal novel strategies to detect &treat this prevalent disease. ..
  50. Decision Making For Active Surveillance in Prostate Cancer Patients and Spouses
    Christian J Nelson; Fiscal Year: 2013
    ..Over the past years, widespread prostate specific antigen (PSA) screening has resulted in the earlier detection of these cancers...
  51. Treatment Effects on Tumor 18F-Choline Metabolism in Advanced Prostate Cancer
    SANDI ALEXANDER KWEE; Fiscal Year: 2010
    ..Our aims are: 1) examine the relationship between changes in tumor 18F-choline uptake and changes in prostate specific antigen level in response to docetaxel treatment of HRPC, 2) examine the time course by which changes in tumor ..
  52. Global and Specific Oxidation Pathways Related to Prostate Cancer, Prospective an
    Tianying Wu; Fiscal Year: 2013
    ..This will identify individuals in need of aggressive treatment and will avoid overtreatment. (2) Predicting the effects of oxidative stress is of great interest, as oxidative stress levels may be modifiable. ..
  53. Ethnicity &Determinants of QoL Following PCa Treatment
    MICHAEL HOWARD ANTONI; Fiscal Year: 2011
    ..g., more advanced disease, higher prostate specific antigen [PSA]), and reduced QoL and survival following treatment even after controlling for sociodemographic and ..
  54. Effects of Stereotype Threat on the Health-Related Outcomes of African Americans
    Paul R Jones; Fiscal Year: 2011
    ..If threat is a problem, the project will develop guidelines for designing health communication and refining cultural competency training and practice that avoid raising stereotype threat. ..
  55. Characterizing Prostate Cancer By ex vivo MRS Signatures
    Leo L Cheng; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Serum prostate specific antigen testing improved early detection of prostate tumors, increased diagnosed prostate cancer (PCa) incidence, and shifted newly detected PCa treatment to earlier stages...
  56. Single Molecule Fiber Arrays for the Detection of Low Abundance Proteins
    David C Duffy; Fiscal Year: 2013
    ..Using single molecule detection, prostate specific antigen (PSA) was detected in serum at concentrations less than 1 femtomolar;current immunoanalyzers have an LOD ..
  57. Anti-GM1b IgM for Detection of Localized Prostate Cancer
    Mepur Ravindranath; Fiscal Year: 2005
    ....
  58. Profiling Urine Glycosylation of PSA and other Glyco-Biomarkers in Prostate Cance
    Lewis Pannell; Fiscal Year: 2009
    ..We observed significant levels of both prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in the urine from healthy individuals, consistent with some ..
  59. GLUCOCORTICOIDS & VITAMIN D: ROLE IN ANTI-TUMOR EFFECTS
    Candace Johnson; Fiscal Year: 2009
    ..prostate cancer (AIPC) with high dose oral calcitriol and dex, we observed a 50% reduction in serum prostate specific antigen (PSA) in 28% of patients...
  60. DIAGNOSTIC CENTER
    M Lucia; Fiscal Year: 2004
    ..assays on peripheral blood with materials sent from several clinical centers; these assays will include prostate specific antigen, luteinizing hormone, testosterone, and dihydrotestosterone...
  61. Targeted prostate biopsy using mathematical optimization
    Christos Davatzikos; Fiscal Year: 2007
    ..has been widely used as a gold standard for the diagnosis and staging of prostate cancer, when elevated prostate specific antigen (PSA) levels are measured...
  62. NORMAL AND ABNORMAL UTERO-VAGINAL DEVELOPMENT
    Gerald Cunha; Fiscal Year: 1991
    ..changes in the expression of prostate-specific secretory markers (prostatic acid phosphatase, prostate specific antigen and peanut lectin binding sites)...
  63. MOLECULAR STAGING OF LYMPH NODES--OUTCOME OF PROSTATE CA
    Anna Ferrari; Fiscal Year: 2000
    ..be estimated from risk factors at presentation: size of the primary (cT stage), Gleason score and serum prostate specific antigen (sPSA) levels, direct evidence for PC metastasis in PLN has been lacking...
  64. PORT-II FOR PROSTATIC DISEASES
    Michael Barry; Fiscal Year: 1999
    ..and urologists, to better define the effectiveness and cost of screening for CAP with the tumor marker prostate specific antigen (PSA), to better define the effectiveness of aggressive treatment of clinically localized prostate ..